Single Center Real Life Experiences in the Treatment of Pediatric, Adolescent and Young Adult ALL Patients Using Commercially Available CAR-T-Cells in Germany – Susceptibility to Bridging Chemotherapy Predicts Response.

Although children, adolescents and young adult patients with ALL have in general a good prognosis relapses occur and patients with a second relapse, a relapse after allogeneic SCT or patients with primary refractory disease have a poor prognosis. In this patient group several studies using second generation CD19 chimeric antigen receptor T- cells (CAR-T cells) demonstrated high efficacy with survival rates of up to 65%. Here we report our first results using commercially available CAR-T-cell product Tisagenlecleucel in patients with ALL.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Peter Bader, Jan Soerensen, Eva Rettinger, Andre Willasch, Franziska Kalensee, Marc Ansari, Christine Wolschke, Richard Noppeney, Gunnar Cario, Guido Kobbe, Roland Meisel, Claudia Rossig, Thomas E. Klingebiel, Ansgar Schulz, Martin Hutter, Evelyn Ullrich, Tags: 395 Source Type: research